RxSight (RXST) EBITDA Margin (2020 - 2026)

RxSight (RXST) has 7 years of EBITDA Margin data on file, last reported at 51.8% in Q1 2026.

• For the quarter ending Q1 2026, EBITDA Margin fell 2979.0% year-over-year to 51.8%; the trailing twelve-month figure through Mar 2026 stood at 36.65% (down 1880.0% YoY), and the FY2025 full-year result was 29.04%, down 954.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 51.8%, down from 28.09% in the prior quarter.
• Across five years, EBITDA Margin topped out at 15.65% in Q4 2024 and bottomed at 197.65% in Q1 2022.
• The 5-year median for EBITDA Margin is 35.43% (2025), against an average of 62.02%.
• The widest annual swing landed in 2022, when EBITDA Margin jumped 12723 bps; it then slumped 2979 bps in 2026.
• A 5-year view of EBITDA Margin shows it stood at 96.76% in 2022, then soared by 67 bps to 31.92% in 2023, then soared by 51 bps to 15.65% in 2024, then tumbled by 80 bps to 28.09% in 2025, then sank by 84 bps to 51.8% in 2026.
• The last three EBITDA Margin figures came in at 51.8% (Q1 2026), 28.09% (Q4 2025), and 31.77% (Q3 2025), per Business Quant data.

Peer Comparison